Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Free Cash Flow: 2013-2024

Historic Free Cash Flow for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$232.8 million.

  • Viridian Therapeutics, Inc.\DE's Free Cash Flow fell 24.62% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.3 million, marking a year-over-year decrease of 65.29%. This contributed to the annual value of -$232.8 million for FY2024, which is 25.81% down from last year.
  • Viridian Therapeutics, Inc.\DE's Free Cash Flow amounted to -$232.8 million in FY2024, which was down 25.81% from -$185.1 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's Free Cash Flow's 5-year high stood at -$29.8 million during FY2020, with a 5-year trough of -$232.8 million in FY2024.
  • For the 3-year period, Viridian Therapeutics, Inc.\DE's Free Cash Flow averaged around -$170.8 million, with its median value being -$185.1 million (2023).
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Free Cash Flow increased by 17.48% in 2020 and then crashed by 95.56% in 2023.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Free Cash Flow stood at -$29.8 million in 2020, then crashed by 84.16% to -$54.9 million in 2021, then plummeted by 72.32% to -$94.6 million in 2022, then crashed by 95.56% to -$185.1 million in 2023, then declined by 25.81% to -$232.8 million in 2024.